Rosuvastatin

Phase 3Terminated

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Elevated High-sensitivity C-Reactive Protein (hsCRP)

Conditions

Elevated High-sensitivity C-Reactive Protein (hsCRP)

Trial Timeline

Feb 1, 2003 → Sep 1, 2008

NCT ID

NCT00239681

About Rosuvastatin

Rosuvastatin is a phase 3 stage product being developed by AstraZeneca for Elevated High-sensitivity C-Reactive Protein (hsCRP). The current trial status is terminated. This product is registered under clinical trial identifier NCT00239681. Target conditions include Elevated High-sensitivity C-Reactive Protein (hsCRP).

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00160745	Phase 2	Completed	—	Sep 1, 2006	Hypercholesterolemia
NCT04846231	Phase 2	Completed	Apr 23, 2021	Jul 19, 2022	Hypercholesterolemia
NCT02561845	Pre-clinical	Withdrawn	Oct 1, 2015	Oct 1, 2015	PCI Patients
NCT02484027	Approved	UNKNOWN	Sep 1, 2015	Sep 1, 2018	Infarction, Anterior Cerebral Artery
NCT02077257	Approved	UNKNOWN	Mar 1, 2014	May 1, 2016	Acute Coronary Syndrome
NCT01837823	Phase 2	Completed	Jul 1, 2013	Apr 1, 2015	Obstructive Coronary Artery Disease
NCT01490398	Approved	Completed	Dec 1, 2011	Oct 1, 2013	Hypertension
NCT01364220	Phase 3	Terminated	Aug 1, 2010	Apr 1, 2013	Stroke
NCT00815659	Approved	Completed	Dec 1, 2008	Mar 1, 2010	Metabolic Syndrome
NCT00747149	Approved	Completed	May 1, 2008	Aug 1, 2009	Type 2 Diabetes
NCT00473655	Approved	Completed	Jan 1, 2007	Feb 1, 2009	Hypertriglyceridemia
NCT00335699	Approved	Completed	Aug 1, 2005	Jan 1, 2007	Hypercholesterolemia
NCT00184951	Phase 2	Completed	Apr 1, 2004	Jul 1, 2005	HIV Infections
NCT00240305	Phase 3	Completed	Apr 1, 2004	May 1, 2006	Metabolic Syndrome
NCT00176332	Phase 2	Completed	Mar 1, 2004	Dec 1, 2006	Heart Failure
NCT00228514	Phase 3	Completed	Feb 1, 2004	Jul 1, 2007	Rosuvastatin
NCT00240266	Phase 3	Completed	Aug 1, 2003	Dec 1, 2004	Metabolic Syndrome
NCT00241488	Phase 3	Completed	Jun 1, 2003	Feb 1, 2007	Hypercholesterolemia
NCT00660764	Pre-clinical	Completed	May 1, 2003	Apr 1, 2005	Hypercholesterolemia
NCT00239681	Phase 3	Terminated	Feb 1, 2003	Sep 1, 2008	Elevated High-sensitivity C-Reactive Protein (hsCRP)

Competing Products

12 competing products in Elevated High-sensitivity C-Reactive Protein (hsCRP)

See all competitors

Product	Company	Stage	Hype Score
Muvalaplin + Placebo	Eli Lilly	Phase 3	77
Baricitinib	Eli Lilly	Pre-clinical	23
TQJ230 + Placebo	Novartis	Phase 3	77
LIK066 + Placebo	Novartis	Phase 2	52
Olpasiran	Amgen	Phase 1	32
Maridebart cafraglutide + Placebo	Amgen	Phase 2	51
Ivabradine	Amgen	Phase 3	76
ALN-PCS02 + Sterile Normal Saline (0.9% NaCl)	Alnylam Pharmaceuticals	Phase 1	30
ISIS-APO(a)Rx + Placebo	Ionis Pharmaceuticals	Phase 2	49
APOC-III-L-Rx + Placebo Comparator	Ionis Pharmaceuticals	Phase 1	30
ISIS 681257 + Placebo	Ionis Pharmaceuticals	Phase 2	49
IONIS-APO(a)-LRx + Sterile Normal Saline (0.9% NaCl)	Ionis Pharmaceuticals	Phase 1	30

Other Products from AstraZeneca

QuetiapineApproved

Dapagliflozin 5 mg + Placebo tabletApproved

QuetiapineApproved

Ticagrelor + ClopidogrelApproved

DurvalumabApproved